The FDA grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/metastatic melanoma

by | Dec 15, 2020

IO Biotech today announced that the FDA has granted breakthrough therapy designation for a combination of the potential therapy IO102 and IO103 with anti-PD-1 mAb for patients with unresectable/ metastatic melanoma.

Press inquiries should be adressed to:

Claus Andersson, PhD

General Partner